Lai Quintin J's Form 4 filing
West Pharmaceutical Services Inc (WST) · filed Sep 14, 2021
- Accession no.
- 0001562180-21-005939
- Filed
- Sep 14, 2021
- Trade date
- Sep 10, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.46M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lai Quintin JCIK 0001744326 | Officer (VP Corp Development & Strategy) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2021 | Common Stock | MOption exerciseAcquired | +8,672 | $59.64 | +$517,198.08 | 10,905.84 | Direct | |
| Sep 10, 2021 | Common Stock | MOption exerciseAcquired | +1,000 | $72.97 | +$72,970 | 11,905.84 | Direct | |
| Sep 10, 2021 | Common Stock | SSaleDisposed | −5,072 | $460.18F1 | −$2,334,032.96 | 6,833.84 | Direct | |
| Sep 10, 2021 | Common Stock | SSaleDisposed | −3,100 | $460.80F2 | −$1,428,480 | 3,733.84 | Direct | |
| Sep 10, 2021 | Common Stock | SSaleDisposed | −1,500 | $462.63F3 | −$693,945 | 2,233.84 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2021 | Common Stock | MOption exerciseDisposed | −8,672 | $0.00 | $0 | 0 | Direct | |
| Sep 10, 2021 | Common Stock | MOption exerciseDisposed | −1,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $459.50 to $460.44, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $460.50 to $461.44, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $462.48 to $462.805, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.